SynCore Biotechnology Co (杏國新藥) has begun the race to introduce SB05PC, its new pancreatic cancer drug, to the Chinese market as a first-line treatment.
The company has begun enrolling patients in a global phase III clinical trial, that is to take place in seven countries, including the US.
The drug would be used as a second-line treatment in combination with gemcitabine for those who have exhausted other commonly prescribed first-line chemotherapy treatments such as FOLFIRINOX.
SB05PC would be competing against PharmaEngine Inc’s (智擎) onivyde, which has been approved and covered by the National Health Insurance (NHI) program since August.
“Gaining marketing approval from the US Food and Drug Administration would greatly improve SynCore’s odds of succeeding in the Chinese market, where the availability of first-line options is lacking, in particular FOLFIRINOX,” SynCore general manager Su Muh-hwan (蘇慕寰) said.
The company would be required conduct a separate clinical trial if it wants to introduce SB05PC as a first-line treatment and tap into the immense Chinese market for pancreatic treatments, which has yet to be dominated by an established product, Su said.
The company has enrolled its second patient in Taiwan for the phase III global trial and should be able to enroll the required 218 patients before the end of next year, Su said.
“Once site visits are completed in the the US and China, the pace of patient enrollments should pick up dramatically,” Su said, adding that health authorities in France, Hungary, South Korea and Russia have approved SB05PC’s phase III global trial.
The company has also applied for FOLFIRINOX to be covered by the NHI, Su said.
“Based on the results of the phase II trial, we are confident that phase III will meet its primary efficacy endpoint and produce a 40 percent improvement in terms of overall survival among enrolled patients,” said Hsieh Ruey-kuen (謝瑞坤), a physician and a director at the Taiwan Cooperative Oncology Group who worked with SynCore in designing SB05PC’s clinical trial parameters.
Phase III is basically the same study as phase II, only with more patients enrolled to meet regulatory requirements, Hsieh said, adding that SB05PC’s toxicity profile is relatively lower compared with other second-line drugs.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day